Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Wayne, Pennsylvania
- Most recent report
- 8-K, filed Aug 6, 2026
- Incorporated
- Delaware
- Filings on record
- 866 filings
- On EDGAR
- CIK 1557746
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company
Financials 8 of 46
News 8 of 153
- 8-K Significant contract Aug 6, 2026
- 8-K Quarterly results Aug 6, 2026
- 8-K Shareholder vote results Jun 4, 2026
- 8-K Quarterly results May 7, 2026
- 8-K Other events Apr 28, 2026
- 8-K Current report on a material event Mar 11, 2026
- 8-K Current report on a material event Mar 10, 2026
- 8-K Quarterly results Feb 26, 2026
Prospectuses and Registrations 8 of 50
- S-3ASR Automatic shelf registration Aug 6, 2026
- S-8 Registration statement for an employee plan Jun 5, 2025
- S-3 Shelf registration statement Feb 27, 2025
- 424B3 Prospectus supplement for an offering Dec 31, 2024
- S-3 Shelf registration statement Dec 19, 2024
- S-8 Registration statement for an employee plan Nov 27, 2024
- S-8 Registration statement for an employee plan May 7, 2024
- S-8 Registration statement for an employee plan May 8, 2023
Proxies 8 of 21
- DEFA14A Extra proxy material Apr 23, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 23, 2026
- DEFA14A Extra proxy material Apr 24, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 24, 2025
- PRE 14A Preliminary proxy statement Apr 14, 2025
- DEFA14A Extra proxy material Apr 25, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 25, 2024
- DEFA14A Extra proxy material Apr 20, 2023
Ownership 8 of 547
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 4 Insider reported a trade Aug 4, 2026
- 4 Insider reported a trade Jun 8, 2026
- 4 Insider reported a trade Jun 8, 2026
- 4 Insider reported a trade Jun 8, 2026
- 4 Insider reported a trade Jun 8, 2026
- 4 Insider reported a trade Jun 8, 2026
- 4 Insider reported a trade Jun 8, 2026
Other 8 of 49
- ARS Annual report sent to shareholders Apr 23, 2026
- ARS Annual report sent to shareholders Apr 24, 2025
- EFFECT Notice that a registration became effective Mar 7, 2025
- CORRESP Reply to SEC staff Mar 5, 2025
- UPLOAD Comment letter from SEC staff Mar 4, 2025
- EFFECT Notice that a registration became effective Dec 31, 2024
- CORRESP Reply to SEC staff Dec 27, 2024
- UPLOAD Comment letter from SEC staff Dec 26, 2024
Everything here comes from Aclaris Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.